Pharmaceutical Consultants Detect Food And Drud Administration Rule Breaking
The US Government Accountability Office GAO has used pharmaceutical consultants to look into people working for the FDA and the results are a damning criticism that the Food and Drug Administration hires criminally convicted doctors to work for it in clinical trials. The FDA are breaking their own rules with this activity by failing to debar anyone who holds a criminal record from working for the Administration.
On average, GAO found that it took the FDA an average of four years to get round to debarring doctors with a conviction. This is sensational when you consider that the FDA is required by law to disqualify any doctor who has been criminally charged in the past. The FDA seems to be ignoring these laws to such an extent that one doctor worked at the FDA for 11 years even though he had been previously charged with 53 counts of criminal activity.
There are many similar cases to this where doctors have committed fraud, bribery and prescribing medicine without a license. Three doctors continue to work for the FDA even though they have public criminal conviction charges.
One of the main charges that the doctors had been found guilty of was falsifying clinical trial data. Participants were made up, they had their consent forced on them and some of the doctors failed to stick to the research plan entirely. And medical devices are one of the most contentious issues in this whole affair. Under present FDA rules, a doctor who has been convicted of a criminal offence is not prohibited from practicing in the medical device industry, which could be putting the lives of millions of people at risk, especially since inhalers used to treat asthma are thought of as a medical device.
Because the FDA is already breaking its own rules and laws governing it, there seems little reason to implement new regulations. Instead, they propose a wide reform of the whole health care system in America. Prosecutions for doctors found to be breaking the law, company executives barred from senior roles in the FDA and a stricter relationship between the FDA and drug companies.

